Can-Fite BioPharma ( (CANF) ) has shared an announcement.
On March 18, 2025, Can-Fite BioPharma Ltd. announced that the FDA approved the compassionate use of its anti-cancer drug Namodenoson for a U.S.-based pancreatic cancer patient. This approval marks a significant milestone for Namodenoson, which is also undergoing various clinical trials for liver and pancreatic cancers. The drug has been granted Orphan Drug Designation by the FDA, providing potential market exclusivity and regulatory advantages. This development reflects Can-Fite’s commitment to addressing unmet medical needs and enhancing its positioning in the biotechnology industry.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs targeting oncological and inflammatory diseases. The company is engaged in advanced clinical stage drug development, addressing multi-billion-dollar markets in cancer, liver, and inflammatory disease treatments. Its lead drug candidates include Piclidenoson for psoriasis and Namodenoson for liver and pancreatic cancers, among others.
YTD Price Performance: -7.82%
Average Trading Volume: 108,063
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $15.94M
Learn more about CANF stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com